Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Escalating R&D woes spur fresh M&A chatter for cash-rich Gilead
9 years ago
R&D
Two years into an R&D overhaul, GSK plans $250M lab project near Philly for another migration of US staffers
9 years ago
R&D
Is Amgen still shooting blanks in its war with payers over Repatha reimbursement?
9 years ago
R&D
GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round
9 years ago
Financing
Startups
Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M
9 years ago
News Briefing
Sputnik 2.0? Chinese research team first to try CRISPR-Cas9 gene-editing tech on a human
9 years ago
China
Medicines Co, Alnylam generate positive buzz with evidence of a durable, 6-month LDL response to PCSK9 rival
9 years ago
R&D
Low-profile BeyondSpring files for $100M IPO to back cancer work; Erytech hammered after it pulls marketing ...
9 years ago
News Briefing
The Parker Institute aims to speed up cancer R&D, carving out duplicate IRBs at top centers
9 years ago
R&D
Roche harnesses a network of academic I/O researchers in $100M global collaborative
9 years ago
R&D
AbbVie, Enanta hep C combo looks stellar in CKD study as rivals hustle along the latest cures
9 years ago
R&D
Pharma
Struggling gene therapy pioneer uniQure brings out the ax, chopping programs and staffers in overhaul
9 years ago
R&D
Promising or inconclusive? Gilead fields PhII GS-4997 data, triggering more pushback on NASH claims
9 years ago
R&D
Puma shares ripped after growing grade 3 diarrhea threat is highlighted in an abstract
9 years ago
R&D
Did Merck KGaA’s aging atacicept just fail a PhIIb lupus trial? Well, yes, but…
9 years ago
R&D
Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study
9 years ago
News Briefing
Step 3: Sanofi commits up to $100M to opt-in on Alnylam’s PhIII RNAi hemophilia trial
9 years ago
R&D
Dynavax shares crater after the FDA rejects Heplisav-B, again, and CEO signals for help
9 years ago
R&D
Under a short assault, Corbus counterattacks with positive PhII data for systemic sclerosis drug
9 years ago
R&D
J&J, GSK stumble coming out of the gate with mixed PhIII rheumatoid arthritis data for sirukumab
9 years ago
R&D
Biotech insider Rich Bagger is out, Gingrich is up in latest reshuffle of Trump’s inner circle
9 years ago
People
Pharma
Bristol-Myers partners with Johns Hopkins on Opdivo pact; A Valeant by any other name…
9 years ago
News Briefing
The longterm implications of the Trump Bump; Let’s try again on drug pricing
9 years ago
Bioregnum
Opinion
Polaris cashes in its chips as Langer-backed Arsia is auctioned off to Eagle for up to $78M
9 years ago
R&D
First page
Previous page
1170
1171
1172
1173
1174
1175
1176
Next page
Last page